866-997-4948(US-Canada Toll Free)

IPX066 Analysis and Estimates from 2013 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 36 Pages


GlobalDatas pharmaceuticals report, IPX066 Analysis and Estimates from 2013 to 2020 provides IPX066 sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the Japan (seven major markets)
  • Analysis and review of IPX066 including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of IPX066 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for IPX066 in the US and EU5
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Parkinsons Disease 5
2.2 Symptoms of Parkinsons Disease 5
2.3 Diagnosis of Parkinsons disease 6
2.4 Parkinsons Disease Treatment Strategies 6
2.5 Parkinsons Disease Market 7
2.6 Epidemiology 7
2.7 Parkinsons Disease by Age and Gender 7
2.8 Etiology 8
2.9 GlobalData Report Guidance 8

3 Parkinsons Disease: Market Characterization 9
3.1 Parkinsons Disease Market 9
3.2 Parkinsons Disease Market Forecasts and CAGR 9
3.3 Factors Affecting Parkinsons Disease Market 10
3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder 10
3.3.2 Increase in Old Age Population 10
3.3.3 Patent Expiry of Prominent Drugs 10

4 Stages of Parkinsons Disease and Comparison of Treatments 11
4.1 The Hoehn and Yahr Scale 11
4.2 Modified Hoehn and Yahr Scale 11
4.3 The UPDRS 12

5 Staging of Parkinsons Disease 15
5.1 Distribution of Parkinsons disease Patients by Age Groups 15
5.2 Distribution of Patients by Stages 15

6 IPX066 16
6.1 Introduction 16
6.2 Mechanism of Action 16
6.3 Clinical Studies 17
6.4 Status of IPX066 18
6.5 Factors Affecting Sales of IPX066 18
6.5.1 IPX066 Used in All Stages of Parkinsons Disease 18
6.5.2 Better Efficacy 18
6.5.3 Not Approved in Japan 18
6.6 Drug Evaluation 19
6.6.1 Drug Risk Benefit Score 19
6.6.2 Intensity of Competition 20
6.7 Sales Forecasts 21
6.7.1 Target Patient Pool for Parkinsons Disease 21
6.7.2 Dosing 22
6.7.3 Market Penetration 22
6.7.4 Annual Cost of Therapy 23
Sales Projections of IPX066 24

7 Parkinson Disease Market: Appendix 32
7.1 Market Definitions 32
7.2 List of Abberiviations 32
7.3 Research Methodology 32
7.3.1 Coverage 32
7.3.2 Secondary Research 33
7.3.3 Forecasting 33
7.3.4 Number of Patients Approved to take the Drug 33
7.3.5 Net Penetration of Drug 33
7.3.6 Net Annual Dosing 34
7.3.7 Annual Cost of Therapy 34
7.3.8 Primary Research 35
7.3.9 Expert Panels 35
7.4 Drug Sales Estimates Model 35
7.5 Contact Us 35
7.6 Disclaimer 36
7.7 Sources 36

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 5
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 11
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 11
Table 4: Four Items, Part 1 of UPDRS 12
Table 5: Thirteen Items, Part 2 of Parkinsons disease 12
Table 6: Fourteen Items, Part 3 of UPDRS 13
Table 7: Fourteen Items, Part 3 of UPDRS 13
Table 8: Distribution of Parkinsons patients according to Hoehn and Yahr Classification 15
Table 9:Comparison of IPX066 with Stalevo 18
Table 10:Drug Risk Benefit Score (DRB)- IPX066 19
Table 11: Results of APEX Parkinsons Disease Phase III Study 19
Table 12: Primary Endpoints Results, Advanced- Parkinsons Disease Phase III Study 19
Table 13: Summary of Adverse Events , Advanced PD Study, Maintenance Phase 20
Table 14: Dosing Details of APEX-PD Clinical Trial 22
Table 15: Annual Cost of IPX066 for Parkinsons Disease, 2010 23
Table 16: IPX066, Parkinsons Disease, Global, Sales Forecasts ($m), 20132020 24
Table 17: IPX066, Parkinsons Disease, The US, Sales Forecasts ($m), 20132020 25
Table 18: IPX066, Parkinsons Disease, The UK, Sales Forecasts ($m), 20132020 26
Table 19: IPX066, Parkinsons Disease, France, Sales Forecasts ($m), 20132020 27
Table 20: IPX066, Parkinsons Disease, Germany, Sales Forecasts ($m), 20132020 28
Table 21: IPX066, Parkinsons Disease, Italy, Sales Forecasts ($m), 20132020 29
Table 22: IPX066, Parkinsons Disease, Spain, Sales Forecasts ($m), 20132020 30

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons disease and Their Potential Sites of Action in the CNS 6
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 7
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 9
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 10
Figure 5: Points Distribution of UPDRS 14
Figure 6: Distribution of Parkinsons patients by Hoehn & Yahr Classification 15
Figure 7: Primary Endpoint, Off Time Reduction , Advanced Parkinsons Disease Phase III Study 17
Figure 8: Secondary Endpoints, Improvement in UPDRS Parts II and III, Advanced Parkinsons Disease Phase III Study Results 17
Figure 9: Drug Model Diagram of IPX066 21
Figure 10: IPX066, Parkinsons Disease, Global, Sales Forecasts ($m), 20132020 24
Figure 11: IPX066, Parkinsons Disease, The US, Sales Forecasts ($m), 20132020 25
Figure 12: IPX066, Parkinsons Disease, The UK, Sales Forecasts ($m), 20132020 26
Figure 13: IPX066, Parkinsons Disease, France, Sales Forecasts ($m), 20132020 27
Figure 14: IPX066, Parkinsons Disease, Germany, Sales Forecasts ($m), 20132020 28
Figure 15: IPX066, Parkinsons Disease, Italy, Sales Forecasts ($m), 20132020 29
Figure 16: IPX066, Parkinsons Disease, Spain, Sales Forecasts ($m), 20132020 30
Figure 17: IPX066, Parkinsons Disease, Global, Sales Distribution by Country ,2020 31
Figure 18: Drug Model Diagram 34
Figure 19: Patients Approved for the Drug 34

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *